Last updated on June 2006

Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation

Brief description of study

The purpose of this study is to evaluate the incidence of neutrophil engraftment after transplantation of one or two cord blood units meeting a predetermined total minimum cell dose of 2.0 x 10 to the seventh total nucleated cell (TNC)/kg.

Detailed Study Description

This is a non-randomized, phase II protocol to evaluate engraftment of cord blood after treatment with myeloablative conditioning of fludarabine, total body irradiation and cyclophosphamide. All patients will receive tacrolimus and mycophenolate mofetil as prophylaxis for graft-vs-host disease. Conditioning Regimen: - Days -10 to -7: Fludarabine 30mg/m2/day IV - Days -7 to -4: TBI 165 centigray BID - Days -3 to -2: Cyclophosphamide 40mg/kg/day IV Day 0: Infusion of Cord Blood Cells Graft-vs-Host Disease Prophylaxis - Day -1: Start tacrolimus 0.03mg/kg/day IV - Day 0: Start MMF 7.5mg/kg IV BID

Clinical Study Identifier: NCT00328237

Contact Investigators or Research Sites near you

Start Over

Nicole Stephens, RN, BSN, OCN

Rocky Mountain Blood and Marrow Transplant Program
Denver, CO United States
  Connect »